Bergapten

Summary

Bergapten (CHEMBL24171) is a phase-3 clinical-stage small-molecule hepatoprotective agent (ATC D05BA03) targeting TAS2R10; indicated across 2 conditions including psoriasis and atopic eczema.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: D05BA03
• Targets: 1 (TAS2R10)
• Indications: 2 conditions
• Chemistry: 216.19 Da · C12H8O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL24171
Name	Bergapten
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2355
ChEBI	CHEBI:18293
ATC	D05BA03
Molecular formula	C12H8O4
Molecular weight	216.19
InChIKey	BGEBZHIAGXMEMV-UHFFFAOYSA-N

SMILES: COC1=C2C=CC(=O)OC2=CC3=C1C=CO3

IUPAC name: 4-methoxyfuro[3,2-g]chromen-7-one

ChEBI definition: A 5-methoxyfurocoumarin that is psoralen substituted by a methoxy group at position 5.

Pharmacological roles (ChEBI): hepatoprotective agent.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Bergaptan, Bergapten, Bergaptene, Geralen, Heraclin, Majudin, Methoxsalen related compound a, NSC-95437, bergapten, SID11113276, SID17389221, SID26747383

Patent coverage: 1,924 distinct patent families (3,967 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,936 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TAS2R10	TAS2R10	Agonist	5.55	2.2%	Q9NYW0

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Lysine-specific demethylase 4E, Amine oxidase [flavin-containing] A, Thyrotropin receptor, Progesterone receptor, Potassium voltage-gated channel subfamily A member 2, Cytochrome P450 1A1, Adenosine receptor A3, Cytochrome P450 2D6, Cytochrome P450 1A2, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 24 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP1A1	7.22	Ki	60	nM	CHEMBL_ACT_18720595
CYP1A2	7.22	Ki	60	nM	CHEMBL_ACT_18720617
CYP1A1	7.1	IC50	80	nM	CHEMBL_ACT_18720594
CYP1A2	7.05	IC50	90	nM	CHEMBL_ACT_18720616
Q63470	5.83	AC50	1489	nM	CHEMBL_ACT_7007532
CYP2D6	5.7	Potency	1995	nM	CHEMBL_ACT_4981968
CYP2C19	5.5	Potency	3162	nM	CHEMBL_ACT_4016343
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_3925053
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_4698930
CYP2C9	5.3	Potency	5012	nM	CHEMBL_ACT_5073226
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5005889
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5070657

Target pathways

Aggregated over 1 target gene(s): TAS2R10.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	TAS2R10
Signaling by GPCR	1	TAS2R10
GPCR downstream signalling	1	TAS2R10
G alpha (i) signalling events	1	TAS2R10
Class C/3 (Metabotropic glutamate/pheromone receptors)	1	TAS2R10
GPCR ligand binding	1	TAS2R10
Sensory Perception	1	TAS2R10
Sensory perception of taste	1	TAS2R10
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	TAS2R10

Dominant GO biological processes

GO term	Targets
detection of chemical stimulus involved in sensory perception of bitter taste	1
signal transduction	1
G protein-coupled receptor signaling pathway	1
sensory perception of taste	1

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676
atopic eczema	3	MONDO:0004980	EFO:0000274

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	TAS2R10
DENATONIUM BENZOATE	ChEMBL	Phase 2	TAS2R10